

## **Pediatric CIRB Meeting Agenda**

**August 13, 2020**

---

---

### **I. Continuing Review**

**AALL08B1**, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)  
(Protocol Version Date 03/13/18)

---

---

### **II. Continuing Review**

**ACNS1422**, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk  
WNT-Driven Medulloblastoma Patients (Protocol Version Date 10/07/19)

---

---

### **III. Continuing Review**

**AOST1321**, Phase II Study of Denosumab (IND #127430, NSC# 744010), a RANK  
Ligand Antibody, for Recurrent or Refractory Osteosarcoma (Protocol Version  
Date 10/22/18)

---

---

### **IV. Continuing Review**

**ARET12P1**, A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy  
Given in the Ophthalmic Artery of Children with Retinoblastoma (Protocol Version  
Date 03/30/16)

---

---

### **V. Continuing Review**

**PBTC-055**, Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ)  
for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive  
or NF1-associated recurrent or progressive gliomas in children and young  
adults (Protocol Version Date 05/29/20)

---

---